Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

Mar 08, 2017
|
staff reporter

NEW YORK (GenomeWeb) — IntegraGen announced today that it has signed an agreement giving Laboratoire Cerba the right to develop a tumor expression test based on its microRNA biomarker miR-31-3p.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  2. Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

  3. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  4. Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

  5. Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.